Suppression of autophagy enhances preferential toxicity of paclitaxel to folliculin-deficient renal cancer cells by Qi Zhang et al.
Zhang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:99
http://www.jeccr.com/content/32/1/99RESEARCH Open AccessSuppression of autophagy enhances preferential
toxicity of paclitaxel to folliculin-deficient renal
cancer cells
Qi Zhang1,2, Shuhui Si2, Sue Schoen2, Jindong Chen2, Xun-Bo Jin1* and Guan Wu2,3,4*Abstract
Background: Paclitaxel, a widely used chemotherapeutic drug, can induce apoptosis in variety of cancer cells. A
previous study has shown preferential toxicity of paclitaxel to FLCN-deficient kidney cancer cell line, UOK257. In this
report, we investigate the cellular and molecular mechanism of paclitaxel-induced autophagy and apoptosis in renal
cancer cells with and without FLCN expression.
Methods: Two pairs of cell lines were used: FLCN siRNA-silenced ACHN cell line (ACHN-5968) and scrambled ACHN
cell line (ACHN-sc); FLCN-null UOK257 cell line and UOK257-2 cell line restored with ectopic expression of FLCN.
Autophagy was examined by western blot, GFP-LC3, transmission electron microscopy, and MDC assay. Cell viability
and apoptosis were detected using MTT assay, DAPI stain and TUNEL assay. After inhibition of autophagy with
3-Methyladenine (3-MA) or Beclin 1 siRNA, cell viability and apoptosis were measured by MTT assay and TUNEL assay.
Results: After paclitaxel treatment, a dose-dependent decrease in cell viability and increase in apoptosis were observed
in FLCN-deficient UOK257 and ACHN-5968 cells compared to their FLCN-expressing counterparts, suggesting that renal
cancer cells without FLCN were more sensitive to paclitaxel. Enhanced autophagy was found to be associated with
paclitaxel treatment in FLCN-deficient RCC cells. The MAPK pathway was also identified as a key pathway for the
activation of autophagy in these kidney cancer cells. Inhibition of phosphorylated ERK with ERK inhibitor U0126 showed
a significant decrease in autophagy. Furthermore, after inhibition of autophagy with 3-Methyladenine (3-MA) or Beclin
1 siRNA, apoptosis induced by paclitaxel was significantly increased in FLCN-deficient UOK257 and ACHN-5968 cells.
Conclusions: Preferential toxicity of paclitaxel to FLCN-deficient kidney cancer cells is associated with enhanced
autophagy. Suppression of autophagy further enhances paclitaxel-induced apoptosis in FLCN-deficient renal cancer
cells. Our results suggest that paclitaxel combined with an autophagy inhibitor might be a potentially more effective
chemotherapeutic approach for FLCN-deficient renal cancer.
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The functional connection between apoptosis and auto-
phagy is a burgeoning area of research and has drawn
intense interest from cancer researchers [1-3]. While
apoptosis involves the activation of catabolic enzymes in
signaling cascades that lead to destruction of cellu-
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stated.autophagy involves the formation of autophagosomal ve-
sicles that engulf unwanted cellular components and im-
paired organelles and fuse with lysosomes for degradation
and recycling [2]. Autophagy has been demonstrated to be
involved in a wide variety of cellular processes, including
cellular homeostasis, energy metabolism, cell death, cell
survival, tissue regeneration, etc. Not surprisingly, auto-
phagy plays critical roles in human disease processes,
including cancer, neurodegenerative diseases, metabolic
disorders, aging, infection and immunity [2].
It appears that the same stimuli, such as anticancer
agents, can induce both apoptosis and autophagy in cellsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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a nonapoptotic form of programmed cell death, the in-
duction of autophagy in cancer cells may lead to cell
death and therefore have a therapeutic effect on cancer
cells [3]. However, autophagy could be activated under
stress such as nutrient deprivation and hypoxia, playing
an important role in cellular protection and cell survival
[4]. Studies have shown that such cellular protection and
survival endowed by autophagy might make cancer cells
resistant to chemotherapy [5]. Therefore, it is essential
to determine the function of autophagy in the process of
anticancer therapy and its connection with apoptosis.
Recently, although several pathways that link between
the apoptotic and autophagic machineries have been re-
ported, a strong causal relationship or interplay between
autophagy and apoptosis in cancer cells has not been
demonstrated adequately [1,2]. The therapeutic potential
of induction or suppression of autophagy in cancer treat-
ment undoubtably depends on understanding the role of
autophagy in cancer cells.
Paclitaxel (Taxol) is an effective mitotic inhibitor and
apoptosis inducer. It has been widely used in chemothe-
rapy for lung cancer, breast cancer, ovarian cancer, and
Kaposi’s sarcoma [6]. It has been shown that in non-small
cell lung carcinoma cells, while paclitaxel treatment leads
to apoptosis, paclitaxel also induces an autophagic re-
sponse that plays a protective role impeding the eventual
cell death [7]. While some recent studies demonstrated
that paclitaxel treatment led to increased autophagy in
lung cancer cells and osteosarcoma cells, and inhibition of
autophagy increased the cytotoxic sensitivity of cells to
paclitaxel [7,8], Veldhoen et al. reported that paclitaxel
could inhibit autophagy in breast cancer cells by blocking
activation of the class III phosphatidyl inositol 3 kinase,
Vps34, and autophagy sensitized cells to paclitaxel toxicity
[9]. These conflicting results suggested that the treatment
effects of paclitaxel on autophagy might be cell-type
dependent. Recently, it has been demonstrated that pacli-
taxel exhibits preferential toxicity to folliculin (FLCN)-
deficient renal cell carcinoma (RCC) line, UOK257, a cell
line which originated from a patient with Birt–Hogg–
Dube (BHD) syndrome [10]. BHD syndrome, caused by
FLCN mutations, is an autosomal dominant genetic dis-
ease characterized by susceptibility to renal cancer, renal
and pulmonary cysts, and noncancerous tumors of the
hair follicles [11]. Function of FLCN has been linked
to mTOR and AMPK signaling pathways [12,13]. In
addition, FLCN was reported to be involved in apoptosis
[12,14-16]. Furthermore, FLCN was recently found to be
associated with the activity of LC3-mediated autophagic
program [17]. These findings might provide new insights
into the treatment of BHD disease. While early-stage
bilateral renal cancer associated with BHD disease could
be managed with partial nephrectomy, an effective curefor BHD disease associated renal cancer has not been
established. The preferential toxicity of paclitaxel to
UOK257 FLCN-deficient cell line suggested that paclitaxel
might be a candidate anticancer drug for FLCN-deficient
tumors [10]. To further determine the cellular response of
FLCN-deficient cell lines treated with paclitaxel, here we
examined apoptosis and autophagy induced by paclitaxel
in human renal cancer cell lines with or without FLCN
expression. Our results indicated that autophagy induced
by paclitaxel in FLCN-null renal cancer cells plays a pro-
tective role, and the inhibition of autophagy could increase




Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were purchased from Gibco (GIBCO,
NY, USA). 3-Methyladenine (3-MA) was purchased from
Sigma (Sigma-Aldrich, USA) and prepared as a stock
solution of 100 mM in phosphate buffered saline (PBS).
Paclitaxel, monodansyl cadaverine (MDC), and bafilo-
mycin A1 were purchased from Sigma. U0126 was pur-
chased from LC laboratories (LC Labs, USA). GFP-LC3
plasmid was obtained from Addgene (Addgene plasmid
24920). HT TiterTACSTM Assay Kit was purchased from
TREVIGEN (TREVIGEN, USA), Beclin 1 siRNA was pur-
chased from Invitrogen (Invitrogen Life Technologies, NY,
USA). Antibodies used in this study included the fol-
lowing: Anti-cleaved Caspase-3, anti-MEK1/2, anti-
phospho-MEK1/2, anti-phospho-ERK1/2, anti-p62 and
anti-Beclin 1 (Cell Signaling Technology, USA); anti-
LC3 polyclonal (Thermo Fisher Scientific, USA); anti-
FLCN antibody (Obtained from the Van Andel Research
Institute).
Cell culture
Two pairs of cell lines were used: FLCN siRNA-silenced
ACHN-5968 cell line and scrambled ACHN line
(ACHN-sc); FLCN-null UOK257 cell line and UOK257-2
line restored with ectopic expression of FLCN. ACHN
was purchased from ATCC, and ACHN-5968 was gene-
rated in our lab. UOK257 cell line was obtained from
NCI, and UOK257-2 was prepared in our lab. All of these
cell lines were cultured in DMEM medium, supplemented
with 10% fetal bovine serum (FBS) and maintained at
37°C with 5% CO2.
Cell viability assay
The viability of cells was measured by MTT assay. Ap-
proximately 2 × 103 cells were cultured in 96-well plates
and treated with various reagents. MTT (5 mg/ml) was
added to each well and cells were cultured at 37°C for
4 hours. Supernatant was removed and 200 μl DMSO
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bance was measured at 570 nm using a microplate
reader (BioTek).
Western blot
Cells were harvested and lysed on ice for 45 min in RIPA
lysis buffer (1 M Tris, PH7.4, 50 mM; NaCl 150 mM; 1%
NP-40; EDTA 1 mM, plus standard protease inhibitor).
The concentration of protein was measured by Nanodrop
(Thermo). Equal amounts of total protein extracts were
loaded and separated in 10% -15% SDS-PAGE gel and
transferred to PVDF membranes. The membranes were
blocked in Tris-buffered saline-Tween-20 (TBST) with 5%
milk for 1 hour and incubated overnight at 4°C with dif-
ferent primary antibodies: mouse monoclonal anti-FLCN
at a dilution of 1:1000, rabbit polyclonal anti-LC3-I/II
(1:2000), rabbit polyclonal anti-p62 (1:2000), rabbit mono-
clonal anti-cleaved caspase-3 antibody (1:1500); mouse
polyclonal anti-MEK (1:2000), rabbit polyclonal anti-phos-
pho-MEK (1:2000); rabbit polyclonal anti-phospho-ERK
(1:2000) or mouse monoclonal anti-Beclin 1(1:2000). The
membranes were washed in TBST and incubated with
secondary antibody at room temperature for two hours.
Proteins were detected with ChemiDoc detection system
(Bio-Rad).
DAPI stain and TUNEL assay
Cell apoptosis was detected using DAPI stain and TUNEL
assay. Cells with indicated reagents treatment were fixed
with methanol/acetone (1:1) for 5 min at room tem-
perature, then washed with phosphate-buffered saline
(PBS) and stained with DAPI (1:2000 dilution, in 1× PBS)
for 10 min. The cells were subsequently rinsed with PBS
and observed under a fluorescent microscope (ZEISS).
To do the TUNEL assay , monolayer cells in 96-well
plate were treated with corresponding reagents and
cultured at 37°C. Cells were subsequently fixed in 3.7%
paraformaldehyde for 7 minutes, and quantitation of
apoptotic cells was measured by in situ colorimetric
TUNEL assay (HT TiterTACSTMAssay kit, TREVIGEN®)
following the manufacturer’s protocol. The results were
immediately analyzed at 450 nm in the microplate reader.
Autophagy assay
Autophagy was detected by transmission electron micros-
copy, GFP-LC3 and MDC assays. For transmission elec-
tron microscopy assay, cells were trypsinized, fixed for
24 hours with 2.5% glutaraldehyde in 0.1 M sodium caco-
dylate, and then fixed for another 30 minutes with 1.0%
osmium tetroxide. Cells were trapped in agarose, treated
with 0.5% uranyl acetate for 1 hour in the dark and dehy-
drated in a graded series of ethanol. They were transi-
tioned to propylene oxide, infiltrated in Epon®/Araldite®
resin for 24 hours, embedded in molds and polymerizedfor 48 hours at 70°C. Blocks were cut to determine area
into 70 nm sections. The thin sections were collected on
mesh nickel grids and stained with aqueous uranyl acetate
and lead citrate. Grids were examined and photographed
with a H-800 transmission electron microscope (Hitachi,
Tokyo, Japan).
For GFP-LC3 assay, cells were cultured in 6-well plates
and transfected with GFP-LC3 (Addgene plasmid 24920)
with Lipofectamine™ 2000 (Invitrogen, USA) following
the manufacturer’s protocol. At 24 hours after transfec-
tion, the cells were treated with paclitaxel (100 nM) or
DMSO control and cultured at 37°C for 24 hours. The
cells were subsequently examined under the fluores-
cence microscope (ZEISS), with 395 nm excitation wave-
length and 509 nm emission filter respectively.
For MDC assay, cells cultured in 6-well plate were
treated with 0.05 mM MDC and incubated at 37°Cfor
20 minutes. After staining, cells were fixed in 4% para-
formaldehyde for 10 minutes and intracellular autophagy
was detected using a fluorescence microscope (ZEISS)
with 380 nm excitation wavelength and 525 nm emission
filter.
MDC and GFP-LC3 assay results were ranked by the
intracellular punctuates per cell: 1—0 to 4 punctuates, 2—
5 to 9, 3—10 to 14, 4—15 to 19 and 5—more than 19. Cell
scores were non-normally distributed and shown as mean
of at least 20 per group, and confirmed by at least three
separate experiments [18].
Beclin 1 siRNA transfection
Cells were seeded in 6-well plates and incubated for
24 hours, then transfected with beclin 1-targeted siRNA or
control random siRNA(Invitrogen) using Lipofectamine™
2000 according to the manufacturer’s protocol. At 24 hours
after transfection, cells were treated with or without pa-
clitaxel for additional 24 hours and collected for western
blot. Transfected cells were also used for MTT and
TUNEL assays.
Statistical analysis
Statistical significances were analyzed by ANOVA and
paired Student t test with Statistics Package for Social
Science (SPSS) software (Version 14). Qualitative data
were expressed as means ± S.D, and p < 0.05 was consi-
dered statistically significant difference.
Results
Paclitaxel induced cytotoxicity and apoptosis in
FLCN-deficient renal cancer cells
To determine whether paclitaxel treatment leads to apop-
tosis in FLCN-deficient renal cancer cells, cell lines with
(ACHN-sc and UOK257-2) and without (ACHN-5968
and UOK257) FLCN expression were treated with pacli-
taxel. The cell viability was analyzed by MTT assay after
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growth by paclitaxel on FLCN-deficient UOK257 and
ACHN-5968 cells was more significant than that on
matched UOK257-2 and ACHN-sc cells, indicating more
severe paclitaxel-induced cytotoxicity to FLCN-deficient
cells. We further analyzed apoptosis in these cell line pairs
by using in situ colorimetric TUNEL assay. As shown in
Figure 1B, paclitaxel could induce apoptosis in all
treated cells with or without FLCN expression. How-
ever, a much greater number of apoptotic cells were
detected in UOK257 and ACHN 5968 lines compared
to UOK257-2 and ACHN-sc lines. The differences were
also dose-dependent and reached maximum at 100 nM
of paclitaxel. After paclitaxel treatment, cell nuclear mor-
phological changes were observed using DAPI staining
assay (Figure 1C). Paclitaxel caused more apoptosis with
destroyed DNA in UOK257 and ACHN 5968 cells (indi-
cated as the strong blue fluorescence). Furthermore, after
the treatment of paclitaxel, the 35 kDa protein caspase-3
was cleaved into 17 kDa fragments in cells with or without
FLCN expression (Figure 1D). The levels of cleaved
caspase-3 were obviously higher in UOK257 and ACHN
5968 cells upon the treatment with 100 nM paclitaxel,
indicating more apoptosis was induced in cells without
FLCN expression. These results supported the conclusion
that paclitaxel induces more apoptosis in FLCN-deficient
renal cancer cells.
Paclitaxel induced autophagy in FLCN-deficient renal
cancer cells
To determine whether paclitaxel induces autophagy as
well in FLCN-deficient renal cancer cells, we measured
the expression of microtubule-associated protein 1 light
chain 3 (LC3) in paclitaxel-treated cells by Western blot.
LC3 is an important autophagy marker recruited to the
autophagosome membrane. LC3 has two isoforms, LC3-I
and LC3-II. During autophagy, LC3-I is conjugated to
autophagic membrane-associated phosphatidylethanol-
amine and converted to LC3-II. Increased LC3-II level,
especially increased LC3-II/LC3-I ratio, may indicate
the occurrence of autophagy [19,20]. To exclude the
possibility that the increased LC3-II levels were resulted
from the accumulation of LC3-II due to downstream
inhibition other than paclitaxel induction, we treated
the cells with paclitaxel in presence or absence of lyso-
somal inhibitor bafilomycin A1. As shown in Figure 2,
although increased LC3-II levels were detected in all of
the bafilomycin A1-treated cells due to inhibition of
lysosomal degradation of LC3-II, LC3-II levels were
even higher in the paclitaxel-treated FLCN-deficient
cells compared to that in the FLCN-expressing cells re-
gardless of balfilomycin A1 (Figure 2A). The paclitaxel-
mediated LC3 expression levels were also measured at
various drug concentrations and different time points withor without bafilomycin A1 treatment (Figure 2B, C). The
paclitaxel treatment led to increase of LC3-II level in a
dose-dependent manner and seemed to peak at 24 hours
in FLCN-deficient cells. To further confirm that paclitaxel
could induce autophagy in FLCN-deficient cells, we exa-
mined the p62 expression by Western blot. The reduced
p62 level usually indicates activation of autophagy in cells
[19,21]. In the absence of lysosomal inhibitor bafilomycin
A1, we observed that expression of p62 protein was de-
creased in paclitaxel-treated FLCN-deficient cells, sugges-
ting that autophagy was activated and the p62 protein was
degraded via autophagy (Figure 2D). The p62 level was
obviously elevated in FLCN-deficient cells treated with
bafilomycin A1 and paclitaxel, indicating autophagy was
blocked by bafilomycin A1 and p62 was accumulated in
these cells (Figure 2D) These results demonstrated that
paclitaxel could induce autophagy in FLCN-deficient cells.
To further confirm the induction of autophagy in these
cells, we examined the autophagosome formation after
paclitaxel treatment using three assays. First, we examined
the autophagosome formation with transmission electron
microscopy assay. Both pairs of cell lines were examined
after paclitaxel treatment. The results showed that in-
creased autophagosome numbers were present in FLCN-
deficient cells (UOK257 and ACHN-5968) (Figure 2E).
We next examined the formation of autophagosome
through the appearance of the punctate structures with
GFP-LC3 assay. We transfected these cells with a GFP-
LC3 plasmid that ectopically expressed LC3 in the affected
cells. The results showed that the FLCN-deficient cells
exhibited a higher number of punctate structures com-
pared to FLCN-expressing UOK257-2 and ACHN-sc cells
(Figure 2F). We further detected autophagy in cells with
monodansyl cadaverine (MDC) staining assay. Since MDC
was demonstrated to have higher affinity for lysosomes, here
we used it as an auxiliary means [22]. Similar to the GFP-
LC3 assay, we analyzed the formation of autophagosomes
under fluorescence microscopy. Again, the FLCN-deficient
cells displayed much higher number of punctate structures
compared to corresponding counterparts (Additional file 1:
Figure S1). These results showed that autophagy was in-
duced by paclitaxel treatment in FLCN-deficient cells.
Paclitaxel induces autophagy in FLCN-deficient cells via
activation of ERK pathway
To explore the molecular mechanism of paclitaxel in-
duced autophagy in FLCN-deficient cells, we examined
the alteration of the ERK pathway, which is known to
be associated with autophagic regulation in lung can-
cer cells [23,24]. As presented in Figure 3, elevated ex-
pressions of phospho-MEK and phospho-ERK were
detected in FLCN-deficient renal cell lines, indicating
that absence of FLCN was connected with the ac-
tivation of the ERK pathway (Figure 3A). Paclitaxel
Figure 1 Paclitaxel induced cytotoxicity and apoptosis in FLCN-deficient renal cancer cells. A. Cells were treated with 100 nM paclitaxel or
a control vehicle, cell viability was measured by MTT assay. Compared with UOK257-2 and ACHN-sc cells, FLCN-deficient UOK257 and ACHN-5968
cells were more sensitive to paclitaxel-mediated cytotoxicity. (*: p < 0.05. UOK257 with Paclitaxel vs UOK257-2 with Paclitaxel; ACHN-sc with
Paclitaxel vs ACHN 5968 with Paclitaxel; n = 15) B. Cells were treated with 50, 80, and 100 nM paclitaxel for 24 hours. TUNEL assay was used for
apoptosis analysis. FLCN-deficient cells (UOK257 and AHN-5968) showed more cell death compared to FLCN-expressing counterparts. (*: p < 0.05.
UOK257 vs UOK257-2; ACHN-sc vs ACHN 5968; n = 15). C. Cells treated with 100 nM Paclitaxel or a control vehicle were stained with DAPI and
analyzed under fluorescence microscope. Bright blue fluorescent signals showed the damaged nuclear DNA due to apoptosis. More bright blue
fluorescent spots were observed in FLCN-deficient cells. Scale bar = 10 μm. D. Cells were treated with 50, 80, and 100 nM paclitaxel for 24 hours,
cleaved caspase-3 and FLCN protein were detected by western blot. Elevated cleaved caspase-3 expression was detected in FLCN-deficient cells.
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Figure 2 Paclitaxel induced autophagy in UOK257 and ACHN-5968 cells. A. UOK257/UOK257-2 and ACHN-sc/ACHN 5968 cells were treated
with 100 nM paclitaxel for 24 hours. In the absence or presence 100 nM bafilomycin A1 for four hours before harvest, elevated LC3-II levels were
detected in FLCN-deficient UOK257 and ACHN-5968 cells by Western blot assay. B. In the absence or presence bafilomycin A1, LC3 protein levels were
examined for cells treated with paclitaxel at various concentrations for 24 h, the highest LC3 level was observed at 100 nM in FLCN-deficient cells.
C. FLCN-deficient cells were treated with 100 nM paclitaxel and harvested at different time intervals with or without bafilomycin A1 treatment. LC3-II
expression peaked at 24 h treatment. D. Cells were treated with 100 nM paclitaxel and harvested with or without bafilomycin A1 treatment. In the
absence of lysosomal inhibitor bafilomycin A1, decreased p62 was observed in paclitaxel-treated FLCN-deficient cells. E. Paclitaxel-induced
autophagosomes in cells were observed using transmission electron microscopy. Autophagosome formation was found in FLCN-deficient
UOK257 and ACHN-5968 cells. Arrows indicate autophagosome structures. Scale bars = 500 nm (*: p < 0.05. UOK257 vs UOK257-2; ACHN-sc vs
ACHN 5968; n = 30). F. Cells were transfected with GFP-LC3 and analyzed under fluorescent microscopy for autophagosomes (*: p < 0.05,
UOK257 vs UOK257-2; ACHN-sc vs ACHN 5968; n = 60). Scale bars = 15 μm.
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sion of phospho-ERK and Beclin 1 in FLCN-deficient
UOK257 and ACHN-5968 cells. Only slightly elevated
phospho-ERK and Beclin 1 were observed in FLCN-
expressing cells (Figure 3B). Additionally, treatment
with the ERK inhibitor U0126 significantly reduced the
expression of LC3, Beclin 1, and phospho-ERK in
UOK257 and ACHN-5968 cells (Figure 3C, D). In
addition, U0126 treatment further enhanced the cyto-
toxicity and apoptosis induced by paclitaxel in these
FLCN-deficient cells (Figure 3E, F). These results further
suggested that paclitaxel induced autophagy in FLCN-
deficient cells via the ERK pathway.Inhibition of autophagy enhanced paclitaxel-induced
apoptosis in FLCN-deficient cells
To determine the impact of autophagy on paclitaxel-
mediated FLCN-deficient cell death, we applied autophagy
inhibitor 3-MA or Beclin 1 siRNA to suppress autophagy
in those cell lines. As showed in Figure 4A, pretreatment
with 5 mM 3-MA led to a significant decrease of LC3-II
levels in FLCN-deficient UOK257 and ACHN-5968 cells,
indicating that autophagy was inhibited by 3-MA in those
cells. No obvious LC3-II changes were observed in FLCN-
expressing cell lines (UOK257-2 and ACHN-sc) with
3-MA treatment. Pretreatment with 3-MA effectively
inhibited cell viability and enhanced paclitaxel-mediated
Figure 3 FLCN reversely regulated paclitaxel-induced autophagy via the ERK 1/2 pathway. A. ERK 1/2 pathway was activated in UOK257
and ACHN-5968 cells. Both P-MEK and P-ERK were increased those cells. B. Western Blot analysis showed that both P-ERK and Beclin 1 proteins were
significantly elevated in FLCN-deficient cells after paclitaxel, compared to controls. C. ERK inhibitor U0126 repressed the expression of LC3-II protein in
FLCN-deficient cells. D. Fewer punctuated dots were detected in GFP-LC3 transfected FLCN-deficient cells after treatment of paclitaxel and U0126
(*: p < 0.05, UOK257 + Paclitaxel vs UOK257 + Paclitaxel + U0126; ACHN 5968 + Paclitaxel vs ACHN 5968 + Paclitaxel + U0126; n = 60). Scale bars = 15 μm.
E. Treatment with U0126 further enhanced preferential toxicity of paclitaxel to FLCN-deficient cells (*: p < 0.05. UOK257 + Paclitaxel vs UOK257 +
Paclitaxel + U0126; ACHN 5968 + Paclitaxel vs ACHN 5968 + Paclitaxel + U0126; n = 15). After treatment with U0126, apoptosis induced by paclitaxel was
significantly increased in FLCN-deficient UOK257 and ACHN-5968 cells (*: p < 0.05. UOK257: Paclitaxel vs Paclitaxel + U0126; ACHN 5968: Paclitaxel vs
Paclitaxel + U0126; n = 15).
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UOK257-2 and ACHN-sc cells (Figure 4B, C). These
results demonstrated that inhibition of autophagy could
enhance paclitaxel-mediated apoptosis and cytotoxicity in
FLCN-deficient renal cancer cells.
Beclin 1 knockdown inhibited autophagy and sensitized
FLCN-deficient cells to paclitaxel
To further confirm the role of autophagy on cell death,
we knocked down another autophagy marker, Beclin 1,
in all four cell lines by the siRNA method. UOK257,
UOK257-2, ACHN-sc, and ACHN-5968 cells were tran-
sfected with Beclin 1 siRNA or a negative control
siRNA, respectively. We then examined the effects ofBeclin 1 knockdown on paclitaxel-mediated apoptosis
and cell viability in these cells. Compared to the treat-
ment with negative control siRNA, Beclin 1 siRNA
remarkably abrogated the paclitaxel-induced LC3-II ex-
pression in FLCN-deficient UOK257 and ACHN-5968
cells regardless of bafilomycin A1treatment (Figure 5A).
The knockdown of Beclin 1 led to a significant increase
of apoptosis and inhibition of cell viability in FLCN-
deficient cells, which was consistent with the results ob-
tained through 3-MA treatment (Figure 5B, Figure 5C).
These data indicated that autophagy provided protection
and survival advantage to FLCN-deficient cells against cell
apoptosis and cell death induced by paclitaxel. Inhibition
of autophagy could increase the paclitaxel-induced
Figure 4 3-MA inhibited autophagy and enhanced apoptosis induced by paclitaxel treatment in FLCN-deficient cells. A. Cells were
pretreated with 5 mM 3-MA for 3 hours and subsequently treated with 100 nM paclitaxel or a control vehicle for 24 hours with or without bafilomycin
A1 treatment. LC3 proteins were dramatically decreased after autophagy inhibitor 3-MA. B. Cells were treated with 3-MA and different concentrations
of paclitaxel, MTT assay showed that cell viability was more significantly reduced in FLCN-deficient cells compared to 3-MA untreated cells (*: p < 0.05.
UOK257 + Paclitaxel vs UOK257 + Paclitaxel + 3-MA; ACHN 5968 + Paclitaxel vs ACHN 5968 + Paclitaxel + 3-MA; n = 15). C. TUNEL assay showed that
more apoptotic cells were detected among FLCN-deficient cells treated with 3-MA and paclitaxel (*: p < 0.05. UOK257: Paclitaxel vs UOK257+ 3-MA;
ACHN 5968: Paclitaxel vs Paclitaxel + 3-MA; n = 15).
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cacy of paclitaxel against these cancer cells.
Discussion
As a cancer chemotherapeutic drug, paclitaxel has been
widely used in chemotherapy for lung cancer, breast
cancer, ovarian cancer, and Kaposi’s sarcoma [6]. Kidney
cancers are known to be resistant to conventional che-
motherapy [25-27]. Gemcitabine in combination with
doxorubicin has only shown some benefit in patients with
certain types of kidney cancer [28]. A recent study hasshown preferential toxicity of mithramycin and paclitaxel
to FLCN-deficient kidney cancer cell line, UOK257 [10]. If
proven, this provides a unique therapeutic opportunity to
a group of tumors related to BHD disease. In this study,
we chose paclitaxel for further study its effects on FLCN-
deficient kidney cancer cells to find a more effective way
to treat these cancer cells. Besides FLCN-deficient cell line
UOK257, a cell line derived from a BHD patient’s kidney
cancer [29], we also employed a RCC cell line, ACHN,
with known FLCN expression and its FLCN expression
could be effectively suppressed with siRNA. Although
Figure 5 Beclin 1 knockdown inhibited autophagy and sensitized FLCN-deficient cells to paclitaxel. A. Cells were transfected with Beclin 1
siRNA or a random siRNA control for 24 hours and subsequently treated with 100 nM paclitaxel for 24 hours with or without bafilomycin A1
treatment, LC3 protein levels were detected using Western blot. Less LC3 proteins were detected in Beclin 1 siRNA treated cells. B. FLCN-deficient
cells transfected with Beclin 1 siRNA or a random siRNA control were treated with different concentrations of paclitaxel. MTT assay showed that
cell viability was obviously decreased after Beclin 1 siRNA treatment (*: p < 0.05. UOK257 + Paclitaxel + random siRNA vs UOK257 + Paclitaxel +
beclin 1 siRNA; ACHN 5968 + Paclitaxel + random siRNA vs ACHN 5968 + Paclitaxel + beclin 1 siRNA; n = 15). C. Number of apoptotic cells increased
after treatment with Beclin 1 siRNA and 100 nM paclitaxel (*: p < 0.05. UOK257: Paclitaxel + random siRNA vs Paclitaxel + beclin 1 siRNA; ACHN
5968: Paclitaxel + random siRNA vs Paclitaxel + beclin 1 siRNA; n = 15).
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we would not expect that silencing FCLN with siRNA in
ACHN cell line would replicate a RCC cell line derived
from a BHD patient, our study did show consistent resultsbetween UOK257 and ACHN cells in respect to paclitaxel
treatment-induced apoptosis and autophagy in the pre-
sence or absence of FLCN. We first demonstrated that
paclitaxel could lead to apoptosis as well as autophagy in
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http://www.jeccr.com/content/32/1/99FLCN-deficient cell lines UOK257 and ACHN-5968. After
paclitaxel treatment, a dose-dependent decrease in cell
viability and increase in apoptosis were observed in both
FLCN-deficient UOK257 and ACHN-5968 cells, while
their FLCN-expressing counterparts showed relatively less
changes. These results suggested that FLCN-deficient
RCC cells were more sensitive to paclitaxel exposure
through apoptosis, indicating that FLCN may play a role
against paclitaxel-induced apoptosis. We further detected
that enhanced autophagy occurred along with apoptosis
after paclitaxel treatment in FLCN-deficient RCC cells
compared to FLCN-expressing counterparts, suggesting
that paclitaxel treatment could also induce autophagy in
FLCN-deficient RCC cell lines. Previous studies have sug-
gested that FLCN was involved in apoptosis. While
Reiman et al. identified that FLCN might up-regulate the
expression of a number of apoptosis genes and activates
apoptosis [14]. Baba et al. found that FLCN interacted
with the Bcl 2 family to inhibit apoptosis in B cells in
FLCN knockout mouse [16]. Interestingly, FLCN, like
tumor suppressor VHL, seems to be associated with the ac-
tivity of LC3-mediated autophagic program, which suggests
that the existence of functional crosstalk between two
major tumor suppressors in renal cancer, VHL and
FLCN, converging on regulation of autophagy [17].
Behrends et al. also suggested that FNIP1, a partner
protein of FLCN, is a part of an autophagy interaction
network [30]. Based on these reports and our data, it
seems that the presence of FLCN can prevent cells
from apoptosis and autophagy following paclitaxel
treatment.
Since existing reports have presented conflicting results
on the effects of paclitaxel treatment on autophagy in dif-
ferent cell types [7-9], it seems plausible that the effects of
paclitaxel on autophagy is cell-type-specific. In addition,
some specific proteins or signal pathways may influence
the regulation of paclitaxel on autophagy and lead to dif-
ferent autophagic effects. It was reported that paclitaxel
could induce autophagy only in Cdx1-expressing colon
cancer cells, but not in Cdx1-deficient colon cancer cells
[31]. In our study, we observed that autophagy was obvi-
ously activated by paclitaxel via the MAPK pathway and
beclin 1 protein in FLCN-deficient renal cancer cells, but
not in FLCN-expressing cells. These results demonstrated
that paclitaxel treatment could specifically sensitize
FLCN-deficient renal cancer cells to paclitaxel toxicity
and induce autophagy in these cells.
In our study, we also found that the MAPK path-
way was activated after paclitaxel treatment in FLCN-
deficient RCC cells and that autophagy was signifi-
cantly decreased after treatment with ERK inhibitor
U0126 in these cancer cells. These results indicated
that MAPK pathway played a key role in the acti-
vation of autophagy in these kidney cancer cells andinhibition of MAPK pathway reduced autophagy in
these cells. To further determine whether paclitaxel
treatment induced autophagy represents synergistic
antineoplastic effects on FCLN-deficient RCC cells or
provides a protective mechanism against apoptosis, we
used autophagy inhibitor and Beclin 1 siRNA to suppress
autophagy. Our experiments demonstrated that increased
apoptosis was detected by direct inhibition of autophagy
with 3-Methyladenine (3-MA) or Beclin 1 siRNA after
paclitaxel exposure in FLCN-deficient UOK257 and
ACHN-5968 cells. These results suggested that in FLCN-
deficient RCC cells paclitaxel treatment-induced autoph-
agy provided a protective mechanism against apoptosis
and other damage. Based on mounting evidence, it
is conceivable that autophagy induced by different
chemotherapeutic agents plays different roles or op-
posite roles in different types of cancer. Genetic, epi-
genetic, and metabolic backgrounds of specific types of
cancer are likely the keys to determine the role of au-
tophagy during chemotherapy. For FLCN-deficient
RCC cells, suppression of autophagy enhances prefer-
ential toxicity of paclitaxel.Conclusions
In summary, our data demonstrated that in FLCN-
deficient renal cancer cells, paclitaxel treatment induced
apoptosis is associated with increased autophagy that
plays a protective role against the treatment. Inhibition
of autophagy significantly enhanced paclitaxel-induced
apoptosis. Our findings suggest that paclitaxel treatment
combined with inhibition of autophagy might be a
potentially more effective chemotherapeutic approach
for FLCN-deficient renal cancer and BHD-related kidney
tumors.Additional file
Additional file 1: Figure S1. Paclitaxel-induced autophagosomes in
cells with or without FLCN expression were detected using MDC assay.
Punctuated areas in cells represent autophagosomes. Cell scores were
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